| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5502077 | WOODWARD | Fatty acid composition |
Mar, 2013
(11 years ago) | |
| US5656667 | WOODWARD | Fatty acid composition |
Apr, 2017
(7 years ago) | |
| US7732488 | WOODWARD | Pharmaceutical composition comprising low concentrations of environmental pollutants |
Jan, 2025
(8 months from now) | |
Lovaza is owned by Woodward.
Lovaza contains Omega-3-Acid Ethyl Esters.
Lovaza has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Lovaza are:
- US5502077
- US5656667
Lovaza was authorised for market use on 10 November, 2004.
Lovaza is available in capsule;oral dosage forms.
Lovaza can be used as use in lipid management.
The generics of Lovaza are possible to be released after 30 January, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-87) | Sep 16, 2012 |
Drugs and Companies using OMEGA-3-ACID ETHYL ESTERS ingredient
Market Authorisation Date: 10 November, 2004
Treatment: Use in lipid management
Dosage: CAPSULE;ORAL
How can I launch a generic of LOVAZA before it's drug patent expiration?
More Information on Dosage
LOVAZA family patents
